Navigation Links
MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
Date:3/13/2008

Combined data from two Phase 3 trials show clinical success rates

statistically equivalent to oral antibiotic therapy

WELLESLEY HILLS, Mass., March 13 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) announced today the presentation of a poster entitled "Topical versus Systemic Antimicrobial Therapy for Treating Infected Diabetic Foot Ulcers: A Randomized, Controlled, Double-Blinded, Multicenter Trial of Pexiganan Cream." The poster will be presented at the Diabetic Foot Global Conference 2008 in Los Angeles on March 13 to 15 by Benjamin A. Lipsky, MD, FACP, FIDSA, Professor of Medicine, University of Washington and Director, Primary Care Clinic, VA Puget Sound Health Care System.

The poster presents results of two Phase 3 clinical studies, individually and combined, comparing the efficacy of an investigational topical antimicrobial peptide preparation, pexiganan acetate cream, against systemic therapy with an oral fluoroquinolone antibiotic, ofloxacin, for mildly infected diabetic foot ulcers. The authors conclude, in part, that, "The rates of clinical cure or improvement (the primary outcome of the trial) for topical pexiganan and oral ofloxacin were statistically equivalent for the combined studies."

Dr. Lipsky commented that, "To my knowledge, these combined studies are the largest on treatment of diabetic foot infections ever conducted, the only ones that have compared these two routes of therapy, and the first to demonstrate the efficacy of a topical antimicrobial in treating diabetic foot infection in active-controlled trials. Furthermore, having an effective topical therapy available as an alternative to systemic treatment focuses attention on the wound and, in the case of pexiganan, uses a new antimicrobial, while avoiding adverse systemic effects and the promotion of antibiotic resistance."

"We are very pleased that these newly analyzed data are being presented for the first time a
'/>"/>

SOURCE MacroChem Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
2. Synbiotics Corporation Announces Human Submission for FluDetect(R)
3. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
4. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
5. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
6. Inclinix Announces New Patent for Expert System Platform
7. Genzyme Announces Presentation of New Positive Data on Carticel(R)
8. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
9. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Circadiance Launches NEW Zzzephyr Seal 28TM 29 for Its SleepWeaver 28TM 29 ADVANCE Mask Now Available in Three Colors 60056 1Circadiance Launches NEW Zzzephyr Seal 28TM 29 for Its SleepWeaver 28TM 29 ADVANCE Mask Now Available in Three Colors 60056 2STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 1STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 2STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 3STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 4STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 5STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 6Pharmalink AB Receives Patent for Nefecon 28R 29 Principle 5674 1Pharmalink AB Receives Patent for Nefecon 28R 29 Principle 5674 2Pharmalink AB Receives Patent for Nefecon 28R 29 Principle 5674 3